A Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after Osimertinib
September 11, 2026
A Phase 1, Open-Label, Multicenter Study of the Pharmacokinetics and Safety of Pralatrexate in Advanced Solid Tumor or Hematological Malignancy with Normal or Mild/Moderate/Severe Hepatic Impairment